Ralph B. D’Agostino

1 month ago | tandfonline.com | Apar Kishor Ganti |Ralph B. D’Agostino |Victoria Allan |Patricia Prince

ABSTRACTAim Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy. Patients & methods US-based electronic medical data from Flatiron Health (01/01/2013–03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.

Jun 1, 2023 | jacc.org | Alexander Lucas |Ralph B. D’Agostino |Jennifer Jordan |Kerryn Reding

Introduction Ascending (AAD) and descending (DAD) thoracic aorta distensibility, and thoracic aorta pulse wave velocity (PWV) reflect vascular stiffening that associates independently with subsequent cardiovascular (CV) events.1 Four to 6 months following cardiotoxic chemotherapy, AAD decreases and PWV increases.2,3 The goal of this prespecified secondary analysis of a previously published4 randomized trial, conducted in collaboration with the Wake Forest NCI Community Oncology Research...

Jun 1, 2023 | jacc.org | Moriah P. Bellissimo |Kerryn Reding |Nathaniel O’Connell |Ralph B. D’Agostino

JACC Journals › JACC: CardioOnc › Archives › Vol. 5 No. 3 IntroductionCancer survivors who received anthracycline-based chemotherapy (ANTH) are at increased risk of cancer therapy–related cardiovascular dysfunction and reduced left ventricular ejection fraction (LVEF), contributing to a heightened risk of developing heart failure (HF).